Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 10;11(6):941.
doi: 10.3390/cells11060941.

Biological Hallmarks and Emerging Strategies to Target STAT3 Signaling in Multiple Myeloma

Affiliations
Review

Biological Hallmarks and Emerging Strategies to Target STAT3 Signaling in Multiple Myeloma

Jianbiao Zhou et al. Cells. .

Abstract

Multiple myeloma (MM) is the second most common hematological malignancy, characterized by an abnormal accumulation of plasma cells in the bone marrow. Signal transducer and activator of transcription 3 (STAT3) is a cytoplasmic transcription factor that modulates the transcription of multiple genes to regulate various principal biological functions, for example, cell proliferation and survival, stemness, inflammation and immune responses. Aberrant STAT3 activation has been identified as a key driver of tumorigenesis in many types of cancers, including MM. Herein, we summarize the current evidence for the role of STAT3 in affecting cancer hallmark traits by: (1) sustaining MM cell survival and proliferation, (2) regulating tumor microenvironment, (3) inducing immunosuppression. We also provide an update of different strategies for targeting STAT3 in MM with special emphasis on JAK inhibitors that are currently undergoing clinical trials. Finally, we discuss the challenges and future direction of understanding STAT3 signaling in MM biology and the clinical development of STAT3 inhibitors.

Keywords: JAK inhibitor; hallmarks of cancer; multiple myeloma; signal transducer and activator of transcription 3 (STAT3); targeted therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Venn diagrams of genes upregulated in MM cell lines after additional IL-6 stimulation. The MM-STAT3 signature contains 15 upregulated genes shared by studies of Brocke-Heidrich K, et al. (B-H.K., ref. [21]) and Tsuyama N (T.N., ref. [22]).
Figure 2
Figure 2
STAT3 regulates the biological hallmarks and enabling characteristics of multiple myeloma. The key mechanisms of action undertaken by STAT3 in facilitating the hallmarks: (1) sustaining MM cell survival and proliferation; (2) regulating tumor microenvironment (bone marrow niche); (3) inducing immunosuppression, and characteristic pathways and essential genes are listed. Genes or pathways in black font represent overexpression or activation, while gene and cell type and function with down arrows in blue font denote decreased expression, or number or function.

Similar articles

Cited by

References

    1. Kumar S.K., Rajkumar V., Kyle R.A., van Duin M., Sonneveld P., Mateos M.V., Gay F., Anderson K.C. Multiple myeloma. Nat. Rev. Dis. Primers. 2017;3:17046. doi: 10.1038/nrdp.2017.46. - DOI - PubMed
    1. Chng W.J., Dispenzieri A., Chim C.S., Fonseca R., Goldschmidt H., Lentzsch S., Munshi N., Palumbo A., Miguel J.S., Sonneveld P., et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014;28:269–277. doi: 10.1038/leu.2013.247. - DOI - PubMed
    1. Tan D., Chng W.J., Chou T., Nawarawong W., Hwang S.Y., Chim C.S., Chen W., Durie B.G., Lee J.H. Management of multiple myeloma in Asia: Resource-stratified guidelines. Lancet Oncol. 2013;14:e571–e581. doi: 10.1016/S1470-2045(13)70404-2. - DOI - PubMed
    1. Fuchsl F., Krackhardt A.M. Adoptive Cellular Therapy for Multiple Myeloma Using CAR- and TCR-Transgenic T Cells: Response and Resistance. Cells. 2022;11:410. doi: 10.3390/cells11030410. - DOI - PMC - PubMed
    1. Lancman G., Sastow D.L., Cho H.J., Jagannath S., Madduri D., Parekh S.S., Richard S., Richter J., Sanchez L., Chari A. Bispecific Antibodies in Multiple Myeloma: Present and Future. Blood Cancer Discov. 2021;2:423–433. doi: 10.1158/2643-3230.BCD-21-0028. - DOI - PMC - PubMed

Publication types

MeSH terms